BHVN Stock Forecast 2025-2026
Distance to BHVN Price Targets
BHVN Price Momentum
10 Quality Stocks Worth Considering Now
Researching Biohaven (BHVN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on BHVN and similar high-potential opportunities.
Latest BHVN Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, BHVN has a bullish consensus with a median price target of $61.00 (ranging from $54.00 to $77.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $28.39, the median forecast implies a 114.9% upside. This outlook is supported by 16 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Douglas Tsao at HC Wainwright & Co., suggesting a 90.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BHVN Analyst Ratings
BHVN Price Target Range
Latest BHVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BHVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Morgan Stanley | Terence Flynn | Overweight | Maintains | $63.00 |
| Mar 5, 2025 | JP Morgan | Tessa Romero | Overweight | Maintains | $68.00 |
| Mar 4, 2025 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $61.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $54.00 |
| Feb 11, 2025 | Deutsche Bank | David Hoang | Buy | Initiates | $65.00 |
| Dec 17, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Dec 17, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $59.00 |
| Dec 4, 2024 | RBC Capital | Leonid Timashev | Outperform | Reiterates | $61.00 |
| Nov 26, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $59.00 |
| Nov 25, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $58.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $59.00 |
| Nov 13, 2024 | RBC Capital | Leonid Timashev | Outperform | Maintains | $66.00 |
| Nov 13, 2024 | TD Cowen | Tyler Van Buren | Buy | Maintains | $75.00 |
| Oct 23, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Oct 4, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Oct 3, 2024 | JP Morgan | Tessa Romero | Overweight | Maintains | $68.00 |
| Sep 24, 2024 | HC Wainwright & Co. | Douglas Tsao | Buy | Reiterates | $59.00 |
| Sep 24, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $0.00 |
| Sep 24, 2024 | B of A Securities | Jason Gerberry | Buy | Maintains | $62.00 |
| Sep 24, 2024 | Bernstein | William Pickering | Outperform | Maintains | $66.00 |
Biohaven Ltd. (BHVN) Competitors
The following stocks are similar to Biohaven based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Biohaven Ltd. (BHVN) Financial Data
Biohaven Ltd. has a market capitalization of $2.95B with a P/E ratio of -3.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -198.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Biohaven Ltd. (BHVN) Business Model
About Biohaven Ltd.
Develops therapies for neurological diseases.
Biohaven Ltd. generates revenue through the development and commercialization of innovative biopharmaceutical therapies targeting neurological and neuropsychiatric conditions. By focusing on unmet medical needs, particularly in migraine relief and neurodegenerative diseases, the company aims to bring advanced treatments to market, leveraging its research platforms for drug discovery.
As a clinical-stage biopharmaceutical company based in New Haven, Connecticut, Biohaven Ltd. is positioned within the biotechnology and pharmaceutical sectors, with a strong emphasis on cutting-edge research and a promising pipeline of therapeutic candidates that could significantly impact healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
256
CEO
Dr. Vladimir Coric M.D.
Country
United States
IPO Year
2017
Website
www.biohaven.comBiohaven Ltd. (BHVN) Latest News & Analysis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
3 days agoPomerantz LLP is investigating claims for Biohaven Ltd (NYSE:BHVN) investors. Interested parties can contact Danielle Peyton at [email protected] or 646-581-9980.
The investigation suggests potential legal issues for Biohaven Ltd, which could impact stock performance and investor confidence, influencing market sentiment and trading behavior.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for buyers of Biohaven Ltd. (NYSE:BHVN) as of March 20, 2025.
The investigation into Biohaven could indicate potential legal issues or financial instability, impacting stock performance and investor sentiment.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors in Biohaven Ltd. (NYSE:BHVN) as of March 17, 2025.
The investigation into Biohaven may indicate legal or financial troubles, potentially impacting stock performance and investor confidence.
BHVN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Biohaven Ltd. investment
10 days agoLevi & Korsinsky is investigating Biohaven Ltd., notifying investors about the commencement of this inquiry as of March 17, 2025.
The investigation could signal potential legal issues or financial concerns for Biohaven Ltd., which may impact its stock price and investor confidence.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for purchasers of Biohaven Ltd. (NYSE:BHVN) as of March 18, 2025.
The investigation suggests potential legal issues for Biohaven, which could impact its stock performance and investor confidence, leading to volatility in its share price.
Levi & Korsinsky has launched an investigation into Biohaven Ltd., notifying investors of the ongoing inquiry as of March 18, 2025.
The investigation into Biohaven Ltd. may indicate potential legal issues or irregularities, impacting the company's stock performance and investor confidence.
Frequently Asked Questions About BHVN Stock
What is Biohaven Ltd.'s (BHVN) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Biohaven Ltd. (BHVN) has a median price target of $61.00. The highest price target is $77.00 and the lowest is $54.00.
Is BHVN stock a good investment in 2025?
According to current analyst ratings, BHVN has 16 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $28.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BHVN stock?
Wall Street analysts predict BHVN stock could reach $61.00 in the next 12 months. This represents a 114.9% increase from the current price of $28.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Biohaven Ltd.'s business model?
Biohaven Ltd. generates revenue through the development and commercialization of innovative biopharmaceutical therapies targeting neurological and neuropsychiatric conditions. By focusing on unmet medical needs, particularly in migraine relief and neurodegenerative diseases, the company aims to bring advanced treatments to market, leveraging its research platforms for drug discovery.
What is the highest forecasted price for BHVN Biohaven Ltd.?
The highest price target for BHVN is $77.00 from at , which represents a 171.2% increase from the current price of $28.39.
What is the lowest forecasted price for BHVN Biohaven Ltd.?
The lowest price target for BHVN is $54.00 from Douglas Tsao at HC Wainwright & Co., which represents a 90.2% increase from the current price of $28.39.
What is the overall BHVN consensus from analysts for Biohaven Ltd.?
The overall analyst consensus for BHVN is bullish. Out of 23 Wall Street analysts, 16 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $61.00.
How accurate are BHVN stock price projections?
Stock price projections, including those for Biohaven Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
